Juno Therapeutics
Biotechnology

Thanks to the $12 billion buyout of its rival, Kite Pharma (NASDAQ:$KITE) by Gilead Sciences (NASDAQ:$GILD) yesterday, Juno Therapeutics (NASDAQ:$JUNO) is having a solid day. Its shares have reached double digits for a second day …

Read